ATE343793T1 - Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit. - Google Patents

Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit.

Info

Publication number
ATE343793T1
ATE343793T1 AT00929470T AT00929470T ATE343793T1 AT E343793 T1 ATE343793 T1 AT E343793T1 AT 00929470 T AT00929470 T AT 00929470T AT 00929470 T AT00929470 T AT 00929470T AT E343793 T1 ATE343793 T1 AT E343793T1
Authority
AT
Austria
Prior art keywords
depression
subject
prognosis
diagnosis
evaluation
Prior art date
Application number
AT00929470T
Other languages
English (en)
Inventor
Roger Nitsch
Christoph Hock
Uwe Otten
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99108723A external-priority patent/EP1050758A1/de
Application filed by Evotec Ag filed Critical Evotec Ag
Application granted granted Critical
Publication of ATE343793T1 publication Critical patent/ATE343793T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
AT00929470T 1999-05-03 2000-05-02 Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit. ATE343793T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108723A EP1050758A1 (de) 1999-05-03 1999-05-03 Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Neurotrophin 3-Spiegel basiert sind
EP99120212 1999-10-09

Publications (1)

Publication Number Publication Date
ATE343793T1 true ATE343793T1 (de) 2006-11-15

Family

ID=26152989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929470T ATE343793T1 (de) 1999-05-03 2000-05-02 Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit.

Country Status (6)

Country Link
US (1) US20080188435A1 (de)
EP (1) EP1173768B1 (de)
AT (1) ATE343793T1 (de)
AU (1) AU4753800A (de)
DE (1) DE60031518T2 (de)
WO (1) WO2000067032A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3497447B1 (de) * 2016-07-08 2024-09-04 Biomerica, Inc. Zusammensetzungen, vorrichtungen und verfahren zum testen der depressionsempfindlichkeit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
PT101051A (pt) * 1991-11-12 1994-02-28 Regeneron Pharma Uso de nt-3, de anticorpo neutralizante anti-nt-3 e de molecula de ribozima ou anti-sentido no fabrico de um medicamento para o tratamento de desordens do sistema nervoso e processo de analise relacionados com nt-3
ATE186841T1 (de) * 1992-09-14 1999-12-15 Regeneron Pharma Methode zum erzeugen von analgie mittels neurotrophine
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression

Also Published As

Publication number Publication date
US20080188435A1 (en) 2008-08-07
WO2000067032A1 (en) 2000-11-09
EP1173768A1 (de) 2002-01-23
DE60031518T2 (de) 2007-08-30
AU4753800A (en) 2000-11-17
EP1173768B1 (de) 2006-10-25
DE60031518D1 (de) 2006-12-07

Similar Documents

Publication Publication Date Title
Walters et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders
ATE283487T1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
Bacon et al. Very Early Changes in Olfactory Functioning Due to Alzheimer's Disease and the Role of Apolipoprotein E in Olfaction a
Treves et al. Presenile dementia in Israel
MacKenzie et al. The prevalence of thrombophilia in patients with chronic venous leg ulceration
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
Horn et al. Hyperphosphatasia‐mental retardation syndrome due to PIGV mutations: expanded clinical spectrum
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE502119T1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
ATE354097T1 (de) Verfahren zur diagnose von leberfibrose.
Wakil et al. Exome sequencing: mutilating sensory neuropathy with spastic paraplegia due to a mutation in FAM134B gene
ATE286253T1 (de) Methoden zur diagnose oder prognose der alzheimerschen krankheit
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
CN101173314A (zh) 检测老年黄斑变性疾病的试剂盒
DE69903278D1 (de) Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
DE60031518D1 (de) Methode zur Diagnostizierung, Prognose oder Evaluation von Behandlung der Depressionen, basiert auf erhöhte Neurotrophin Concentrationen in zerebrospinale Flüssigkeit.
ATE284538T1 (de) Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen
ATE494556T1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
ATE485515T1 (de) Verfahren zur diagnose einer person mit multipler sklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties